All stock lists
BeOne Medicines Ltd. (ONC)
United States · Delayed Price · Currency is USD
Pharmaceutical Preparations
373.45-4.18 (-1.11%)
Insider Score
––Not scored
ONC Insider Score
Insiders filed in the last 90 days, but none of those trades qualified for scoring — round-trip buys and filings whose price is far off the market are excluded.
ONC analyst forecast
ONC analyst consensus
Moderate Buy7 ratings
Buy 7 Hold 0 Sell 0
Based on each firm’s most recent rating in the last 3 months — one vote per firm, so a desk that reiterates weekly does not count three times.
ONC 12-month price target
$422.50+13.6% upsideaverage of 2 firms
$425.00High
$420.00Low
Best analysts covering ONC
- RBC Capital100%success rate · 5 calls
- Guggenheim100%success rate · 4 calls
- TD Cowen100%success rate · 1 call
- Citigroup100%success rate · 1 call
Measured by us from each firm’s own rating dates and this stock’s split- and dividend-adjusted closes. How we calculate this.
ONC analyst ratings
| Firm | Price target | Action | ||||
|---|---|---|---|---|---|---|
| Morgan Stanley | — | $425.00 | +15.5% | — | 2026-10-16 | |
| — | RBC Capital | Outperform | — | — | Reiterated | 2026-10-08 |
| — | Truist Securities | Buy | — | — | Reiterated | 2026-10-07 |
| Truist Financial | — | $420.00 | +15.0% | — | 2026-10-07 | |
| — | JP Morgan | Overweight | — | — | Reiterated | 2026-10-01 |
| — | Barclays | Overweight | — | — | Reiterated | 2026-09-10 |
| — | TD Cowen | Buy | — | — | Reiterated | 2026-08-06 |
| — | RBC Capital | Outperform | — | — | Reiterated | 2026-08-06 |
| — | Truist Securities | Buy | — | — | Reiterated | 2026-08-06 |
| — | Guggenheim | Buy | — | — | Reiterated | 2026-08-06 |
| — | Barclays | Overweight | — | — | Reiterated | 2026-08-06 |
| — | Citizens | Market Outperform | — | — | Reiterated | 2026-08-06 |
| — | JP Morgan | Overweight | — | — | Reiterated | 2026-07-23 |
| — | Barclays | Overweight | — | — | Reiterated | 2026-07-14 |
| — | Jefferies | Buy | — | — | Upgraded | 2026-07-13 |
| — | RBC Capital | Outperform | — | — | Reiterated | 2026-07-07 |
| — | Truist Securities | Buy | — | — | Reiterated | 2026-07-07 |
| — | Citizens | Market Outperform | — | — | Reiterated | 2026-07-01 |
| — | RBC Capital | Outperform | — | — | Reiterated | 2026-06-02 |
| — | Leerink Partners | Outperform | — | — | Reiterated | 2026-05-15 |
| — | RBC Capital | Outperform | — | — | Reiterated | 2026-05-07 |
| — | Barclays | Overweight | — | — | Reiterated | 2026-05-07 |
| — | Guggenheim | Buy | — | — | Reiterated | 2026-05-07 |
| — | Truist Securities | Buy | — | — | Reiterated | 2026-05-07 |
| — | Jefferies | Hold | — | — | Downgraded | 2026-03-16 |
| — | RBC Capital | Outperform | — | — | Reiterated | 2026-02-27 |
| — | Truist Securities | Buy | — | — | Reiterated | 2026-02-27 |
| — | Guggenheim | Buy | — | — | Reiterated | 2026-02-27 |
| — | Barclays | Overweight | — | — | Reiterated | 2026-02-27 |
| — | Barclays | Overweight | — | — | Reiterated | 2026-02-04 |
| — | RBC Capital | Outperform | — | — | Reiterated | 2025-11-18 |
| — | Citigroup | Buy | — | — | Reiterated | 2025-11-10 |
| — | RBC Capital | Outperform | — | — | Reiterated | 2025-11-07 |
| — | Citizens | Market Outperform | — | — | Reiterated | 2025-11-07 |
| — | Morgan Stanley | Overweight | — | — | Reiterated | 2025-10-20 |
| — | JP Morgan | Overweight | — | — | Reiterated | 2025-10-08 |
| — | RBC Capital | Outperform | — | — | Reiterated | 2025-08-07 |
| — | Guggenheim | Buy | — | — | Reiterated | 2025-08-07 |
| — | JP Morgan | Overweight | — | — | Reiterated | 2025-07-17 |
| — | RBC Capital | Outperform | — | — | Reiterated | 2025-07-16 |
| — | Morgan Stanley | Overweight | — | — | Reiterated | 2025-06-27 |
| — | JP Morgan | Overweight | — | — | Reiterated | 2025-06-27 |
| — | RBC Capital | Outperform | — | — | Reiterated | 2025-06-27 |
| — | RBC Capital | Outperform | — | — | Reiterated | 2025-05-08 |
| — | Guggenheim | Buy | — | — | Reiterated | 2025-05-08 |
| — | RBC Capital | Outperform | — | — | Reiterated | 2025-04-28 |
| — | TD Securities | Buy | — | — | Reiterated | 2025-04-24 |
| — | JP Morgan | Overweight | — | — | Reiterated | 2025-04-21 |
| — | Guggenheim | Buy | — | — | Reiterated | 2025-04-16 |
| — | Guggenheim | Buy | — | — | Reiterated | 2025-04-10 |
| — | Macquarie | Outperform | — | — | Reiterated | 2025-02-28 |
| — | Citizens Capital Markets | Market Outperform | — | — | Reiterated | 2025-02-28 |
| — | TD Cowen | Buy | — | — | Reiterated | 2024-11-13 |
| — | JP Morgan | Overweight | — | — | Reiterated | 2024-10-22 |
| — | JP Morgan | Overweight | — | — | Reiterated | 2024-08-20 |
| — | Citigroup | Buy | — | — | Reiterated | 2024-08-08 |
ONC earnings vs. estimates
| Quarter | EPS est. | EPS actual | Revenue est. | Revenue actual |
|---|---|---|---|---|
| 2026-02-26 | 1.60 | 0.58 | $1.47B | $1.50B |
| 2026-05-06 | 0.73 | 1.96 | $1.44B | $1.51B |
| 2026-08-05 | 1.63 | 2.05 | $1.62B | $1.71B |
| 2026-11-05 | 1.89 | 0.00 | $1.75B | $0 |
Disclaimer — Informational only — not investment advice. Insider transaction data is sourced from SEC Form 4 filings; market data from public feeds and may be delayed. The Insider Score is a proprietary score for research purposes and does not predict future performance. Always do your own research.